Good ANDA Submission Practices

On 26 January 2022 the FDA issued the final guidance for industry.

This guidance is intended to assist applicants preparing to submit to FDA abbreviated new drug applications (ANDAs). This guidance highlights common, recurring deficiencies that may lead to a delay in the approval of an ANDA. It also makes recommendations to applicants on how to avoid these deficiencies with the goal of minimizing the number of review cycles necessary for approval.

Read more online 
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /